Full Answer
How much did ClimaCell raise?
Weather intelligence platform ClimaCell today announced that it has raised a $77 million Series D funding round led by private equity firm Stonecourt Capital, with participation by Highline Capital. This brings the company’s total funding to about $185 million.
What is the new name of ClimaCell?
In addition to the new funding, ClimaCell announced that it has changed its name to Tomorrow.io, with “The Tomorrow Companies Inc.” as its new legal name.
How does ClimaCell collect weather data?
Originally, ClimaCell/Tomorrow.io built out a novel technology to collect weather data using wireless network infrastructure and IoT devices. That’s where the “cell” in ClimaCell came from.
Why ClimaCell liners?
Unlike other 2-piece insulation systems, ClimaCell liners are manufactured with pre-formed hinges to improve thermal performance and save you time in your pack-out operation. Cotton fiber, macerated paper, and other starch alternatives lack structure and tend to flop in the box. ClimaCell liners are sturdy, for a secure fit. Who uses ClimaCell?
Who owns ClimaCell?
Shimon ElkabetzSince being founded in 2016, Tomorrow.io has raised more than $185 million in funding....Tomorrow.io.TypePrivateFounded2016FounderShimon Elkabetz Itai Zlotnik Rei GofferHeadquartersBoston, Massachusetts , U.S.Area servedWorldwide4 more rows
Who owns Tomorrow io?
Shimon Elkabetz is the Co-founder and CEO of Tomorrow.io (formerly ClimaCell). He served in the Israeli Air Force for 11 years where he experienced multiple near-death weather-related experiences - stoking a deep fascination with weather.
Is tomorrow io a public company?
Dec 7 (Reuters) - Weather and security platform Tomorrow.io will go public through a merger with a blank-check firm in a deal worth nearly $1.2 billion, the companies said on Tuesday. The deal with special purpose acquisition company (SPAC) Pine Technology Acquisition Corp (PTOC.
How good is tomorrow Io?
Tomorrow.io has an overall rating of 4.8 out of 5, based on over 76 reviews left anonymously by employees. 93% of employees would recommend working at Tomorrow.io to a friend and 88% have a positive outlook for the business. This rating has been stable over the past 12 months.
Where is tomorrow IO based?
Boston, MassachusettsTomorrow.io is located in Boston, Massachusetts, United States .
How much is IO app tomorrow?
completely freeWeather App Pricing As we mentioned, Tomorrow.io offers you 100% of its features completely free.
How accurate is ClimaCell?
ClimaCell's solution offers 90% correlation to ground truth versus radar's 50% — a key measure of accuracy — making it extremely reliable. ClimaCell is now on a mission to map the world's weather data.
Why do we use climacell?
Diagnostics. ClimaCell is used to protect biologics, reagents, blood samples, and other temperature sensitive assists to and from the lab.
What is the primary material used in a climacell?
The first step in the recycling process is making sure a product sorts with like materials. ClimaCell's primary material is kraft paper, which sorts alongside cardboard. It's flat design allows it to glide over star screens at Material Recovery Facilities just like cardboard, ensuring it sorts properly.
Why do climacells repel water?
ClimaCell liners repel water to protect the integrity of the insulation inside while also absorbing excess condensation, so your products don't arrive wet on hot days. Ships Flat. Molded coolers take up a lot of space in trucks and warehouses.
Can a climacell ship flat?
Unlike rigid Styrofoam coolers, ClimaCell box liners ship and store flat until you’re ready to use them, saving you on freight costs and warehouse space in your facility. Assembling an insulated shipper is extremely easy.
Tomorrow.io Comparisons
aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cill
Tomorrow.io Signals
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Who is the CEO of Climacell?
That’s where the “cell” in ClimaCell came from. But as the company’s CEO and co-founder Shimon Elkabetz told me, while the company isn’t abandoning this approach, its focus today is much broader. “The mission is really to help countries, businesses, organizations, to better manage their weather-related challenges,” he said.
How much is Climacell funding?
This brings the company’s total funding to about $185 million. In addition to the new funding, ClimaCell announced that it has changed its name ...
Does Climacell have satellites?
ClimaCell plans to launch its own satellites to improve its weather predictions. The weather data and forecasting startup ClimaCell today announced that it plans to launch its own constellation of small weather satellites. These radar-equipped satellites will allow ClimaCell to improve its ability to get a better picture ...
What is Cyclacel Pharmaceuticals?
(NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the Oppenheimer 31st Annual Healthcare Conference, a virtual event, on Thursday, March 18, 2021 at 9:20 AM (EDT). Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and progress in key programs. Cyclacel will host one-on-one meetings with investors during the event. A live webcast of the presentation will be available through the Company's website: www.cyclacel.com. The webcast will be archived for 90 days. About Cyclacel Pharmaceuticals, Inc. Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com. Forward-looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts Company:Paul McBarron, (908) 517-7330, [email protected] Investor Relations:Russo Partners LLC, Jason Assad, (212) 845-4253, [email protected] © Copyright 2021 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.
What is Cyclacel's goal?
Uncontrolled cell division is a hallmark of tumor growth, and Cyclacel aims to tackle that facet of cancer through several pathways. Cyclacel has two main drug candidates in its pipeline, fadraciclib and CYC140.
How many patients will be in the scleroderma trial in 2022?
The trial is expected to enroll 45 patients by early 2022, and preliminary data is expected in the first half of next year. Systemic Sclerosis is a rare, chronic autoimmune disease of the skin, and is better known as scleroderma. The disease can involve numerous organs of the body, and is slowly progressive.
